HomeCompareMLLCF vs JEPQ

MLLCF vs JEPQ: Dividend Comparison 2026

MLLCF yields 40.32% · JEPQ yields 11.10%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MLLCF wins by $191.2K in total portfolio value
10 years
MLLCF
MLLCF
● Live price
40.32%
Share price
$4.96
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$236.0K
Annual income
$40,141.97
Full MLLCF calculator →
JEPQ
JPMorgan Nasdaq Equity Premium Income ETF
● Live price
11.10%
Share price
$55.52
Annual div
$6.16
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$44.8K
Annual income
$2,152.59
Full JEPQ calculator →

Portfolio growth — MLLCF vs JEPQ

📍 MLLCF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMLLCFJEPQ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MLLCF + JEPQ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MLLCF pays
JEPQ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MLLCF
Annual income on $10K today (after 15% tax)
$3,427.42/yr
After 10yr DRIP, annual income (after tax)
$34,120.67/yr
JEPQ
Annual income on $10K today (after 15% tax)
$943.83/yr
After 10yr DRIP, annual income (after tax)
$1,829.70/yr
At 15% tax rate, MLLCF beats the other by $32,290.97/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MLLCF + JEPQ for your $10,000?

MLLCF: 50%JEPQ: 50%
100% JEPQ50/50100% MLLCF
Portfolio after 10yr
$140.4K
Annual income
$21,147.27/yr
Blended yield
15.06%
📊

Analyst Conviction Gap

Where Wall Street is split right now

MLLCF
Analyst Ratings
2
Hold
Consensus: Hold
Altman Z
-1.2
Piotroski
1/9
JEPQ
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MLLCF buys
0
JEPQ buys
0
No recent congressional trades found for MLLCF or JEPQ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMLLCFJEPQ
Forward yield40.32%11.10%
Annual dividend / share$2.00$6.16
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$236.0K$44.8K
Annual income after 10y$40,141.97$2,152.59
Total dividends collected$178.0K$16.3K
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: MLLCF vs JEPQ ($10,000, DRIP)

YearMLLCF PortfolioMLLCF Income/yrJEPQ PortfolioJEPQ Income/yrGap
1← crossover$14,732$4,032.26$11,930$1,110.39+$2.8KMLLCF
2$21,315$5,551.80$14,133$1,224.34+$7.2KMLLCF
3$30,314$7,507.11$16,632$1,340.46+$13.7KMLLCF
4$42,415$9,978.09$19,454$1,457.97+$23.0KMLLCF
5$58,431$13,047.54$22,626$1,576.08+$35.8KMLLCF
6$79,320$16,798.63$26,175$1,694.09+$53.1KMLLCF
7$106,185$21,312.20$30,133$1,811.32+$76.1KMLLCF
8$140,281$26,663.87$34,531$1,927.17+$105.8KMLLCF
9$183,022$32,921.38$39,403$2,041.08+$143.6KMLLCF
10$235,976$40,141.97$44,787$2,152.59+$191.2KMLLCF

MLLCF vs JEPQ: Complete Analysis 2026

MLLCFStock

Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus. The company develops MP0310, which is in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist that activates immune cells in the tumor, which is in Phase I clinical trials; and MP0274 that is in Phase I clinical trials for HER2-positive cancers. It also develops MP0423 for treating COVID-19; MP0533, a CD3 T cell candidate for acute myeloid leukemia; and MP0250 for vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin to increase half-life. Molecular Partners AG has agreements and collaboration with Novartis AG to develop, manufacture, and commercialize DARPin-conjugated radioligand therapies; Amgen SA; Allergan, Inc.; and discovery alliance with AbbVie Inc. in ophthalmology, as well as other third-party collaborators. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.

Full MLLCF Calculator →

JEPQETF

The fund seeks to achieve this objective by (1) creating an actively managed portfolio of equity securities comprised significantly of those included in the fund’s primary benchmark, the Nasdaq-100 Index (the Benchmark), and (2) through equity-linked notes (ELNs), selling call options with exposure to the Benchmark. It is non-diversified.

Full JEPQ Calculator →
📬

Get this MLLCF vs JEPQ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MLLCF vs SCHDMLLCF vs JEPIMLLCF vs OMLLCF vs KOMLLCF vs MAINMLLCF vs XYLDMLLCF vs QYLDMLLCF vs VYM

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.